HUTCHMED to Announce 2025 Final Results

Rhea-AI Summary

HUTCHMED (Nasdaq/AIM: HCM; SEHK:13) will announce its final results for the year ended December 31, 2025 on Thursday, March 5, 2026.

Management will host two webcast presentations for analysts and investors with Q&A. The English webcast is at 8:00 am EST and the Chinese (Putonghua) webcast at 8:30 am HKT. Slides and replays will be available via the company website.

Key Figures

Results date: March 5, 2026 Results release time: 6:00 am EST English webcast time: 8:00 am EST +1 more

4 metrics

Results date March 5, 2026 Final results for year ended December 31, 2025

Results release time 6:00 am EST Final results announcement on March 5, 2026

English webcast time 8:00 am EST Analyst/investor webcast on March 5, 2026

Chinese webcast time 8:30 am HKT Putonghua webcast on March 6, 2026

Market Reality Check

Price: $14.57 Vol: Volume 21,388 is about 53...

low vol

$14.57 Last Close

Volume Volume 21,388 is about 53% of the 45,786 share 20-day average, indicating muted trading ahead of the results date announcement. low

Technical Shares at $14.57 are trading below the 200-day MA of $15.29 and about 25% under the 52-week high of $19.50.

Peers on Argus

HCM fell 1.42% while close peers showed mixed moves: INDV and KNSA declined, BHC...

HCM fell 1.42% while close peers showed mixed moves: INDV and KNSA declined, BHC, SUPN, and PBH gained. The mixed peer direction suggests the move was more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Jan 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 13	Phase III results	Positive	+2.3%	Publication of SACHI Phase III savolitinib+osimertinib results in The Lancet.
Jan 06	Phase III topline	Positive	+2.8%	Phase III ESLIM-02 sovleplenib trial met primary endpoint in wAIHA.
Jan 04	Trial progression	Positive	-2.0%	Initiation of Phase III stage of surufatinib combo trial in pancreatic cancer.
Dec 30	NDA acceptance	Positive	-1.5%	China NMPA accepted savolitinib NDA with priority review for gastric cancer.
Dec 29	NDA acceptance	Positive	-2.7%	China NMPA accepted fanregratinib NDA with priority review for ICC.

Pattern Detected

Recent news has been largely positive on clinical and regulatory fronts, yet price reactions have been mixed, with several positive updates followed by negative moves.

Recent Company History

Over the last few months, HUTCHMED has reported multiple late-stage clinical and regulatory milestones. In Dec 2025, NDAs for savolitinib and fanregratinib in China were accepted with priority review, but shares declined after those announcements. In early Jan 2026, positive Phase III data for sovleplenib in wAIHA and publication of SACHI Phase III results in The Lancet were followed by modest gains. Today’s earnings date notice comes after this series of clinically positive but market‑mixed catalysts.

Market Pulse Summary

This announcement sets the timetable for HUTCHMED’s 2025 final results, including English and Chines...

Analysis

This announcement sets the timetable for HUTCHMED’s 2025 final results, including English and Chinese webcasts for analysts and investors. It follows several recent late‑stage clinical and regulatory milestones in China across oncology and hematology. Investors may focus on how those developments translate into revenue trends, R&D spending, and updated guidance. Key watchpoints include the company’s commercialization progress for approved assets and any commentary on timelines for ongoing NDAs and Phase III programs.

AI-generated analysis. Not financial advice.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT).

HUTCHMED management will host two webcast presentations for analysts and investors to discuss the final results, followed by Q&A sessions. The English webcast will be held on Thursday, March 5, 2026, at 8:00 am EST (1:00 pm GMT / 9:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT / 12:30 am GMT on Friday, March 6, 2026 (7:30 pm EST on Thursday, March 5, 2026).

Both webcasts will be available live via the website of the Company at www.hutch-med.com/event/. The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
Deutsche Numis	Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith	+44 20 7260 1000

FAQ

When will HCM announce its 2025 final results?

HUTCHMED will announce 2025 final results on March 5, 2026 at 6:00 am EST. According to the company, the announcement covers the year ended December 31, 2025 and will be followed by management webcasts and Q&A for investors and analysts.

What are the webcast times for HUTCHMED's HCM results presentation?

The English webcast is at 8:00 am EST and the Chinese webcast at 8:30 am HKT. According to the company, both webcasts include presentations followed by Q&A and will be accessible live on the company's event webpage.

How can investors access HCM's March 5, 2026 webcasts and materials?

Investors can access live webcasts and slides via the company's event page at www.hutch-med.com/event/. According to the company, the presentation will be available to download shortly before the webcast and a replay will be posted after the event.

Will HUTCHMED provide a replay of the March 5, 2026 presentation for HCM?

Yes. According to the company, a replay will be available on the company's website shortly after the event. The presentation slides will also be available to download shortly before the live webcast begins for on‑demand viewing.

What languages and time zones will HCM's webcasts cover on March 5–6, 2026?

HUTCHMED will run an English webcast timed for 8:00 am EST and a Chinese (Putonghua) webcast timed for 8:30 am HKT. According to the company, the schedule is organized to serve global analysts and investors across multiple time zones.